Phosphorus balance and prostate cancer.

Area of Science:

• Urology
• Endocrinology
• Nutritional Science

Background:

• Prostatic diseases, including Benign Prostatic Hyperplasia (BPH) and Carcinoma of the Prostate (CaP), are highly prevalent in aging men.
• Carcinoma of the Prostate (CaP) is a leading cause of cancer death in men, with increasing mortality rates.
• Current understanding of CaP etiology and pathogenesis remains limited, prompting research into preventive strategies.

Purpose of the Study:

• To investigate the potential role of 1,25-(OH)2D, the active form of vitamin D, in reducing the risk of BPH and CaP.
• To explore the link between dietary factors, specifically phosphorus intake and fructose consumption, and serum 1,25-(OH)2D levels.
• To assess whether dietary determinants of hypophosphatemia can mitigate the risk of developing age-related prostatic diseases.

Main Methods:

• Review of existing studies on vitamin D metabolites and prostate health.
• Analysis of research linking dietary phosphorus and fructose intake to serum phosphate and 1,25-(OH)2D levels.
• Correlation of high serum 1,25-(OH)2D levels with reduced risk of poorly differentiated and advanced CaP.

Main Results:

• Elevated serum levels of 1,25-(OH)2D are associated with a decreased risk of BPH and CaP.
• Men with higher 1,25-(OH)2D levels show a reduced risk of advanced and poorly differentiated CaP.
• Dietary factors like low phosphorus intake and fructose consumption can increase 1,25-(OH)2D levels by inducing hypophosphatemia.

Conclusions:

• Dietary strategies that promote hypophosphatemia, thereby increasing 1,25-(OH)2D levels, may offer a preventive approach for prostatic diseases in aging men.
• The active vitamin D metabolite, 1,25-(OH)2D, shows promise in reducing the incidence and severity of BPH and CaP.
• Further research into the therapeutic and preventive potential of modulating vitamin D and phosphate levels is warranted, considering the limitations of hypercalcemic activity.